In the News

Seven Biopharma Trends to Watch in 2022, Genetic Engineering & Biotechnology News

January 06, 2022

Partner David Schwartz spoke to Genetic Engineering & Biotechnology News about current key trends in biopharma, including the recent record-breaking financing of biotechnology companies by both private and public investors. Biotech companies going public in 2022 are likelier to do so via traditional initial public offerings (IPOs), as share prices have risen faster than special purpose acquisition company (SPAC) IPO companies. “Trading for these SPAC companies is down post-closing, as opposed to IPOs,” David said. “At least recent IPOs continue to trade up after closing initially. So, it looks like more of a long-term play for VCs and private equity to get out via the IPO as opposed to the SPAC.”

Read the full Genetic Engineering & Biotechnology News article >>